TABLETS: 30. Dosage:
Should only be used as monotherapy in advanced NSCLC in patients who have previously received treatment with cytotoxic chemotherapy. Should not be chewed, crushed or divided. Not recommended for use in children or adolescents as safety and effectiveness in these populations has not been studied.
250 mg (1 tablet) daily, with or without food. Not to be chewed, crushed or divided.
No dosage adjustment is required on the basis of patient age, body weight, gender, ethnicity or renal function.
Patients with poorly tolerated diarrhea or skin adverse drug reactions may be successfully managed by providing a brief (14 days) therapy interruption followed by reinstatement of the 250 mg dose.
Not recommended for use in children or adolescents as safety and effectiveness in these populations has not been studied. Prescribing Restrictions:
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy. Contra-Indications:
Known severe hypersensitivity to the active substance or to any of the excipients of the product. Special Precautions:
Please refer to the manufacturer for further details. Side Effects:
Please refer to the manufacturer for further details. Drug Interactions:
Drugs that induce, inhibit or are metabolised by CYP3A4, e.g. rifampicin, itraconazole, ketoconazole, clotrimazole and ritonavir. Drugs that cause significant sustained elevations in gastric pH. Metoprolol, warfarin.